VK2735: a maintenance study asks how much treatment can be spaced out
Viking reported a maintenance experiment after 21 weeks of weekly VK2735.
Development event: September 22, 2026. Written September 23 UTC as reconstructed history, linked to the compound overview; this was not published contemporaneously.
Viking reported a maintenance experiment after 21 weeks of weekly VK2735. Over the next 12 weeks, the combined every-two-week groups retained 90% of their prior mean weight loss, and the combined monthly groups retained 85%, versus 61% in the placebo group. Those groups contained 37, 65 and 27 participants respectively. These percentages describe retained prior loss, not new percentage reductions in body weight. Company topline release.
The release's 97% figure belongs to one every-two-week cohort, not the pooled monthly result. One monthly cohort excluded an outlier. The small groups, short maintenance period and sponsor-reported analysis limit conclusions about durable maintenance, adherence and safety; an oral maintenance component was still planned.
The useful change in the story is the question being tested: whether a response achieved on weekly treatment can be maintained with a different interval. It does not replace the separate placebo-controlled 78-week VANQUISH studies or establish an approved regimen. The Phase 3 records describe a different treatment period and population design.
No verified trial identifier for this particular maintenance experiment was established in the sources reviewed, so this entry does not attach a guessed NCT number. Viking's dated company resources (below) remain relevant as the developer pursues multiple formulations and treatment patterns. This update does not estimate the cost of those programs.
Viking Therapeutics — company resources
At June 30, Viking reported $125.8 million of cash and equivalents and $375.9 million of short-term investments, totaling $501.7 million. Restricted cash of $0.2 million is separate. First-half operating cash use was $239.1 million, compared with $99.4 million a year earlier; the net loss was $286.3 million. The balance sheet lists lease obligations but no separate borrowing balance. Development spending and the cost of preparing larger trials make the cash-flow trend relevant. A July shelf registration represents financing capacity, not proceeds already received. Form 10-Q filed July 29, shelf prospectus.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment. The development or financing event discussed in this update is dated 2026-09-22. Read the previous compound account.